Tucatinib for Metastatic HER2+ Breast Cancer and Brain Metastases: Patient Selection

Ruta Rao, MD, discusses her rationale for treating metastatic HER2+ breast cancer with a tucatinib-containing regimen based on data from the HER2CLIMB trial.

Related Videos
Experts on breast cancer
Experts on breast cancer
Experts on RCC
Experts on RCC
Experts on breast cancer
Hope S. Rugo, MD, an expert on breast cancer
Related Content